CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
以工程化免疫学应对 CAR-T 细胞的挑战
英文原题：Combating challenges in CAR-T cells with engineering immunology.
查看英文原题
Combating challenges in CAR-T cells with engineering immunology.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
嵌合抗原受体（CAR）T细胞（CAR-T）标志着朝着开发安全有效的个体化抗癌治疗迈出了重要一步。CAR-T 策略通过对患者T细胞进行工程化改造，使其能够特异性结合肿瘤特异性抗原。CAR-T 是清除残留化疗耐药肿瘤细胞的第二波攻势策略。尽管在多种血液系统恶性肿瘤和实体瘤中显示出实用的抗肿瘤能力，但抗原逃逸、肿瘤浸润/穿透以及毒性副作用等问题限制了CAR-T 疗法的长期使用。然而，免疫工程学已开发利用人干细胞为基础的CAR-T 疗法以及CAR-M（巨噬细胞）疗法的发展，以克服传统CAR-T 疗法的缺点。在本综述中，我们将重点讨论CAR-T 疗法面临的挑战，并通过工程免疫学在癌症免疫治疗中加以应对。
展开英文摘要原文
Chimeric antigen receptors (CAR) T cells (CAR-T) mark a significant step towards producing safe and effective personal anticancer treatments. CAR-T strategies engineers the T cells from the patients to allow specific binding to a tumour-specific antigen.
CAR-Ts are a second-wave offensive strategy to clear out remaining chemotherapy-resistant tumour cells. Though showing practical antitumor abilities in multiple haematological malignancies and solid tumour cancers, the issues of antigen escape, tumour infiltration/penetration, and toxicity side effects limit the usage of prolonged CAR-T therapies.
However, engineering immunology has exploited human stem cell-based CAR-T therapies and the development of CAR-M (macrophage) therapies to combat the disadvantages of conventional CAR-T therapies. In this review, we will highlight the challenges of CAR-T therapies and combat them with engineering immunology for cancer immunotherapy.
论文信息
- 作者
- Wang CY、Ting Cheung SP、Sugimura R
- 单位
- School of Biomedical Sciences, LKS Faculty of Medicine, The University of Hong Kong, Hong Kong, Hong Kong SAR, China.Hong Kong
- 文献类型
- 综述
- 期刊
- Frontiers in cell and developmental biology2022
- 原文标识
- PubMed 36299480 · DOI 10.3389/fcell.2022.969020
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →